Journal of Clinical Oncology
Articles in this Issue
Non-invasively collected buccal cell mRNA and potential for a novel breast cancer signal.
e12539 Background: Breast cancer remains the most frequently diagnosed cancer globally, despite current available diagnostic methods such as mammograms an...
Anxiety, depression, fear of cancer recurrence (FCR) and health-related quality of life (HRQL) in people with melanoma receiving adjuvant therapies.
9566 Background: One year ofadjuvant anti-programmed cell death protein-1 (anti-PD1) or dabrafenib-trametinib are standards of care for patients (pts) wit...
Glutaminase isoform expression in cancer: Implications for metabolic adaptation and therapy.
3078 Background: Glutamine is a critical amino acid involved in various metabolic pathways, particularly in cancers where its importation is significantly...
Efficacy and safety of CDK4/6 inhibitors in HER2-positive breast cancer: A systematic review and meta-analysis.
e13013 Background: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, including Palbociclib, Ribociclib, and Abemaciclib, have demonstrated significant effi...
First-line serplulimab and bevacizumab combined with nab-paclitaxel/gemcitabine followed by mFOLFOX in advanced pancreatic cancer: A phase II trial.
4162 Background: Patients with advanced pancreatic cancer (PC) have a poor prognosis, as this 'cold' tumor shows limited responsiveness to mono-immunother...
Plasma extracellular vesicles as biomarkers of primary versus acquired resistance to immune checkpoint inhibitors (ICI) in patients (pts) with solid tumors.
2551 Background: Plasma extracellular vesicles (pEVs) have emerged as promising biomarkers in the field of oncology. They can be obtained through minimall...
PSMA-PET as a way to choose oligometastatic patients for intermittent androgen deprivation: Extended follow-up of a prospective cohort of patients.
e17113 Background: The use of PSMA PET/CT is better established for the staging of high-risk localized and biochemical recurrent prostate cancer; however...
Survival for colon adenocarcinoma in a hospital-based cancer registry in Cali, Colombia.
e15687 Background: Survival estimations for colon adenocarcinoma (CA) have changed in recent decades due to screening strategies and advances in treatment...
Efficacy of pemetrexed-based regimens in primary central nervous system lymphoma: A single-center experience.
e19078 Background: Primary central nervous system lymphoma (PCNSL) is an aggressive non-Hodgkin’s lymphoma with limited treatment options and overall poor...
Radical surgery with adjuvant therapy in advanced oral tongue cancer: Survival trends and functional outcomes.
e18027 Background: Advanced oral tongue cancer (T3 or T4) is a challenging malignancy requiring aggressive multimodality treatment. This study retrospecti...
Electronic patient-reported outcomes (ePRO) in patients with advanced melanoma receiving immune checkpoint inhibitors: Insights from the Canopy ePRO system.
11126 Background: Health-related quality of life (HRQoL) outcomes are prognostic in melanoma. There is little data comparing HRQoL during nivolumab (nivo)...
Allogeneic stem cell transplantation-related outcomes in myelodysplastic syndromes.
6567 Background: Allogeneic stem cell transplantation (SCT) is the only known curative modality in myelodysplastic syndromes (MDS). Its use has historical...
miRNA(s) expression as predictive biomarkers in recurrent/metastatic cervical cancer: The NRG Oncology/GOG-0240 NIH Cancer Moonshot.
5523 Background: Chemotherapy + pembrolizumab +/- bevacizumab (BEV) is the standard treatment for recurrent/metastatic (R/M) cervical cancer (CC). GOG-024...
Real-world retrospective analysis of the mutation and co-mutation landscape of ERBB2 in advanced NSCLC.
e15155 Background: ERBB2 oncogenic mutations (ERBB2m) have emerged as a significant actionable driver in non-small cell lung cancer (NSCLC) with approved...
Automated prediction of response to neoadjuvant chemotherapy from digitized H&E slides of pre-treatment core needle biopsies in INFORM (TBCRC 031) patients with low stromal TILs.
611 Background: We previously performed anautomated analysis of whole slide images (WSI) of H&E-stained pre-treatment core needle biopsies (CNBs) from...
Liquid-based kidney injury molecule-1 (KIM-1) as a diagnostic and prognostic indicator in renal cell carcinoma: A systematic review and meta-analysis.
e16515 Background: Noninvasive biomarkers for renal cell carcinoma are vital but scarce. Kidney injury molecule-1 (KM-1) is a transmembranous glycoprotein...
Efficacy and safety of adjuvant chemotherapy for locally advanced cervical carcinoma: An updated systematic review and meta-analysis of individual patient data and aggregate data.
e17518 Background: Cervical cancer is the fourth most common cancer among women globally. Adjuvant chemotherapy (ACT) is added to concurrent chemo-radioth...
Detection of KMT2A partial tandem duplication (PTD) in AML by whole genome sequencing (WGS): Addressing limitations of traditional techniques in the era of revumenib approval.
6532 Background: The menin inhibitor revumenib was recently FDA approved for treating patients with relapsed or refractory KMT2A-rearranged (rKMT2A) acute...
Trends in bladder cancer mortality: The influence of tobacco use and sociodemographic factors in the United States over two decades.
e16621 Background: Despite significant advancements in bladder cancer treatment, mortality rates remain high due to the disease's complexity. The effects...
Demographics and outcomes of cancer patients on Medicaid versus private insurance admitted to the hospital in a national sample.
e13823 Background: Cancer is the second leading cause of death in the United States and one of the leading causes of hospital admissions and disability in...
First data from phase 1b/2 EPCORE NHL-4: Epcoritamab (Epcor) in Chinese patients (Pts) with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
e19001 Background: DLBCL comprises 38% of all non-Hodgkin lymphoma (NHL) in China. Outcomes for R/R DLBCL remain poor despite treatment (tx) advances incl...
Computational pathology-informed immune biomarker for trastuzumab benefit in HER2+ breast cancer: Validation in NSABP B-41 clinical trial.
595 Background: Trastuzumab, a targeted therapy, considerably improves survival outcomes in HER2+ breast cancer patients (pts). However, identifying pts m...
The molecular landscape of immunotherapy treatment and advanced disease in head and neck squamous carcinoma (HNSCC).
6032 Background: Advanced head and neck squamous cell carcinoma (HNSCC) exhibits variable responses to immunotherapy, highlighting the need to understand...
Impact of declining renal function on bladder cancer (BC) mortality in the U.S. (1999-2023): A regression analysis using the CDC WONDER database.
e16619 Background: BC is associated with significant renal-related mortality. This is attributed to chemotherapy, acute kidney injury (AKI), chronic kidne...
Elucidating the epigenetic landscape of non-muscle invasive bladder cancer.
e16580 Background: Non-muscle invasive bladder cancer (NMIBC) presents a significant clinical challenge due to its high recurrence rate. Recently, a deepe...